FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031103658> ?p ?o ?g. }

• W2031103658 endingPage "798" @default.
• W2031103658 startingPage "793" @default.
• W2031103658 abstract "1. The effect of pretreatment with bacterial endotoxin (LPS, 10 micrograms, i.v., 24 h) on the bradykinin B1 and B2 receptor-induced oedema in the rat paw, and the interaction of B1-mediated responses with other inflammatory mediators, was investigated. 2. Intraplantar (i.pl.) injection of the selective B1 agonist, des-Arg9-BK (DABK, 100 nmol) in naive animals pretreated with the angiotensin converting enzyme inhibitor, captopril caused a small increase in paw volume (0.04 +/- 0.003 ml, mean +/- s.e. mean, n = 6), while the B2-selective agonist, tyrosine8-bradykinin (T-BK, 3 nmol) induced marked oedema (0.36 +/- 0.02 ml). However, i.pl. injection of DABK (3-300 nmol) in rats pretreated with LPS (24 h beforehand) resulted in a marked dose- and time-related increase in paw volume, with mean ED50 of 24.1 nmol. In contrast, oedema caused by T-BK (3 nmol) was reduced by 79 +/- 4% in animals treated with LPS when compared with naive animals. 3. Oedema caused by prostaglandin E2 (PGE2, 10 nmol) was unaffected by LPS treatment, while oedema induced by histamine (100 nmol), 5-hydroxytryptamine (5-HT, 10 nmol) and substance P (SP, 3 nmol) was reduced (P < 0.05). 4. The selective B1 antagonist, des-Arg9[Leu8]-BK (100-300 nmol), produced dose-dependent inhibition of DABK (100 nmol)-induced paw oedema in LPS-treated animals with mean IC50 of 134 nmol, while the selective B2 antagonists, Hoe 140 and NPC 17731 (each 10 nmol), had no effect. 5. Treatment of animals with dexamethasone (0.5 mg kg-1, s.c.) 24 or 48 h prior to LPS injection resulted in a graded inhibition of DABK (100 nmol)-induced oedema formation (58 +/- 3 and 82 +/- 2%, respectively), and almost reversed to control value oedema formation induced by T-BK (3 nmol) in LPS-pretreated rats. Cycloheximide (1 mg kg-1, s.c.) or indomethacin (2 mg kg-1, i.p.) pretreatment 24 and 1 h prior to LPS injection, respectively, markedly inhibited DABK (100 nmol)-induced paw oedema (98 +/- 2 and 50 +/- 4%, respectively). 6. Intraplantar injection of submaximal dose of DABK (10 nmol) in LPS-treated rats produced modest paw oedema (0.09 +/- 0.03 ml). However, i.pl. injections of PGE2, prostacyclin (PGI2), calcitonin-gene-related peptide (CGRP), SP, 5-HT, or platelet activating factor (PAF) (each 1 nmol), which alone caused little or no paw oedema, resulted in a potentiation of the DABK-induced oedema. The increases in paw volume (in ml) were: PGE2 + DABK (0.31 +/- 0.03), PGI2 + DABK (0.39 +/- 0.02), CGRP+DABK (0.35 +/- 0.04), DABK+SP (0.33 +/- 0.04), DABK + 5-HT (0.40 +/- 0.02) and DABK+PAF (0.38 +/- 0.016) ml. In contrast, histamine (1 nmol) was ineffective in potentiating the response to DABK. 7. The selective B1 receptor antagonist, DALBK (100-300 nmol), produced dose-dependent inhibition of paw oedema potentiation induced by co-injection of DABK and other mediators with mean ID50S (nmol) of: 180, 160, 139 and 135 in the presence of PGE2, PGI2, SP and 5-HT, respectively. 8. These results demonstrate that DABK-induced increase in paw volume in LPS-treated rats is probably mediated by induction of B1 receptors, associated with downregulation of B2 receptors. The induction of B1 receptors by LPS is sensitive to dexamethasone and cycloheximide treatment and requires activation of cyclo-oxygenase pathway. In addition, B1 receptors, when upregulated following LPS treatment, can interact in a synergistic manner with several inflammatory mediators such as PGI2, PGE2, CGRP, PAF and 5-HT. Such results indicate that induction of the B1 receptor might have a significant pathophysiological role in modulating chronic inflammatory diseases." @default.
• W2031103658 created "2016-06-24" @default.
• W2031103658 creator A5000542876 @default.
• W2031103658 creator A5004656528 @default.
• W2031103658 creator A5063730890 @default.
• W2031103658 date "1996-03-01" @default.
• W2031103658 modified "2023-09-27" @default.
• W2031103658 title "Upregulation of B1 receptor mediating des-Arg9-BK-induced rat paw oedema by systemic treatment with bacterial endotoxin" @default.
• W2031103658 cites W1489119117 @default.
• W2031103658 cites W1505408758 @default.
• W2031103658 cites W1764686129 @default.
• W2031103658 cites W1966637576 @default.
• W2031103658 cites W1978934209 @default.
• W2031103658 cites W1979316500 @default.
• W2031103658 cites W1979921010 @default.
• W2031103658 cites W1981856263 @default.
• W2031103658 cites W1982392080 @default.
• W2031103658 cites W1984380422 @default.
• W2031103658 cites W1991983815 @default.
• W2031103658 cites W1993779216 @default.
• W2031103658 cites W2005889776 @default.
• W2031103658 cites W2013813492 @default.
• W2031103658 cites W2014624116 @default.
• W2031103658 cites W2020493471 @default.
• W2031103658 cites W2021311015 @default.
• W2031103658 cites W2027571552 @default.
• W2031103658 cites W2028344754 @default.
• W2031103658 cites W2030180213 @default.
• W2031103658 cites W2041560709 @default.
• W2031103658 cites W2042303125 @default.
• W2031103658 cites W2045246923 @default.
• W2031103658 cites W2045562907 @default.
• W2031103658 cites W2045696948 @default.
• W2031103658 cites W2046093902 @default.
• W2031103658 cites W2050517158 @default.
• W2031103658 cites W2056436777 @default.
• W2031103658 cites W2058532018 @default.
• W2031103658 cites W2068591703 @default.
• W2031103658 cites W2071100896 @default.
• W2031103658 cites W2071732985 @default.
• W2031103658 cites W2076075625 @default.
• W2031103658 cites W2080913361 @default.
• W2031103658 cites W2085948321 @default.
• W2031103658 cites W2087599314 @default.
• W2031103658 cites W2101979009 @default.
• W2031103658 cites W2105429058 @default.
• W2031103658 cites W2119724776 @default.
• W2031103658 cites W2136602916 @default.
• W2031103658 cites W2152924254 @default.
• W2031103658 cites W2316798722 @default.
• W2031103658 cites W2318473077 @default.
• W2031103658 cites W2416890084 @default.
• W2031103658 cites W2434393937 @default.
• W2031103658 cites W4232414191 @default.
• W2031103658 cites W62570931 @default.
• W2031103658 doi "https://doi.org/10.1111/j.1476-5381.1996.tb15262.x" @default.
• W2031103658 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1909403" @default.
• W2031103658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8851492" @default.
• W2031103658 hasPublicationYear "1996" @default.
• W2031103658 type Work @default.
• W2031103658 sameAs 2031103658 @default.
• W2031103658 citedByCount "77" @default.
• W2031103658 countsByYear W20311036582012 @default.
• W2031103658 countsByYear W20311036582013 @default.
• W2031103658 countsByYear W20311036582014 @default.
• W2031103658 countsByYear W20311036582015 @default.
• W2031103658 countsByYear W20311036582016 @default.
• W2031103658 countsByYear W20311036582017 @default.
• W2031103658 countsByYear W20311036582018 @default.
• W2031103658 countsByYear W20311036582019 @default.
• W2031103658 countsByYear W20311036582020 @default.
• W2031103658 crossrefType "journal-article" @default.
• W2031103658 hasAuthorship W2031103658A5000542876 @default.
• W2031103658 hasAuthorship W2031103658A5004656528 @default.
• W2031103658 hasAuthorship W2031103658A5063730890 @default.
• W2031103658 hasBestOaLocation W20311036582 @default.
• W2031103658 hasConcept C118303440 @default.
• W2031103658 hasConcept C126322002 @default.
• W2031103658 hasConcept C134018914 @default.
• W2031103658 hasConcept C170493617 @default.
• W2031103658 hasConcept C185592680 @default.
• W2031103658 hasConcept C2776533618 @default.
• W2031103658 hasConcept C2776885963 @default.
• W2031103658 hasConcept C2777956040 @default.
• W2031103658 hasConcept C2778122271 @default.
• W2031103658 hasConcept C2778938600 @default.
• W2031103658 hasConcept C2779479957 @default.
• W2031103658 hasConcept C2779591629 @default.
• W2031103658 hasConcept C42533223 @default.
• W2031103658 hasConcept C71924100 @default.
• W2031103658 hasConcept C84393581 @default.
• W2031103658 hasConcept C98274493 @default.
• W2031103658 hasConceptScore W2031103658C118303440 @default.
• W2031103658 hasConceptScore W2031103658C126322002 @default.
• W2031103658 hasConceptScore W2031103658C134018914 @default.
• W2031103658 hasConceptScore W2031103658C170493617 @default.
• W2031103658 hasConceptScore W2031103658C185592680 @default.
• W2031103658 hasConceptScore W2031103658C2776533618 @default.

• next